Technology

iCardiac Technologies is offering the pharmaceutical industry’s most advanced ECG-based analytical toolkit for new product development improving both the accuracy and reproducibility of ECG-based measurements for clinical trials through the use of advanced signal processing algorithms.

iCardiac Technologies provides a set of advanced ECG biomarkers and services, which significantly improve ability to predict compound’s pro-arrhythmic potential, rigorously characterize the drug’s effect on the repolarization process, and ultimately stratify patient populations into the groups that should and should not take the drug.

Benefits

iCardiac’s analytical services provide several important benefits:

Rigorous characterization of drug’s propensity to cause dangerous arrhythmias in specific patient populations through unique ECG biomarkers.

Characterization of specific ion channel abnormalities.

Earlier and more effective elimination of potentially cardiotoxic compounds.

Compliance with the FDA E14 guidance for conducting “thorough QT” studies.